Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
نویسندگان
چکیده
Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clinical course of patients with heart failure reduced ejection fraction. This study sought to mutual empagliflozin MRAs in EMPEROR-Reduced (Empagliflozin Outcome Trial Patients With Chronic Heart Failure Reduced Ejection Fraction). Secondary analysis that compared effects versus placebo 3,730 a fraction, whom 71% used at randomization. The on primary endpoint, most efficacy endpoints, safety were similar receiving or not an MRA (interaction p > 0.20). For cardiovascular death, hazard ratios for effect 0.82 (95% confidence interval [CI]: 0.65 1.05) users 1.19 CI: 1.71) nonusers = 0.10); pattern was seen all-cause mortality 0.098). Among baseline, group 35% less likely than those initiate treatment following randomization (hazard ratio: 0.65; 95% 0.49 0.85). 22% discontinue 0.78; 0.64 0.96). Severe hyperkalemia common group. In EMPEROR-Reduced, use did reduce adverse renal outcomes. Treatment associated discontinuation MRAs. Fraction [EMPEROR-Reduced]; NCT03057977)
منابع مشابه
Mineralocorticoid receptor antagonists and mortality in heart failure with concurrent atrial fibrillation.
متن کامل
Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed‐Methods Study
BACKGROUND Mineralocorticoid receptor antagonists (MRAs) are the most underutilized pharmacotherapy for heart failure. Minimal data are available on the barriers to MRA adoption from the perspective of prescribing clinicians. METHODS AND RESULTS A mixed-methods study consisting of a survey (n=50), focus groups (n=39), interviews (n=6) with clinicians at a single US Department of Veterans Affa...
متن کاملThe Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients
Heart failure (HF) remains a leading cause of cardiovascular morbidity and mortality worldwide. Mineralocorticod receptor (MR) antagonists (spironolactone and eplerenone) have been studied in HF patients and in patients with acute coronary syndrome or post-myocardial infarction and left ventricular (LV) dysfunction, as well as hypertensive subjects without HF symptoms. It has suggested that min...
متن کاملMineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
BACKGROUND Mineralocorticoid receptor antagonists (MRAs) have been associated with improved patient outcomes in patients with heart failure with reduced ejection fraction (HFrEF) but not preserved ejection fraction (HFpEF). We conducted a systematic review and meta-analysis of selective and nonselective MRAs in HFrEF and HFpEF. METHODS We searched Cochrane Central Register of Controlled Trial...
متن کاملMineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. These clinical benefits are observed in addition to those of angiotensin converting enzyme inhibitors or...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2021
ISSN: ['1558-3597', '0735-1097']
DOI: https://doi.org/10.1016/j.jacc.2021.01.044